Houssein Ayoub

List of Publications by Year
in descending order

48 papers	4,656 citations	279487 23 h-index	253896 43 g-index
83 all docs	83 docs citations	83 times ranked	3967 citing authors

#	Article	IF	Citations
1	Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. New England Journal of Medicine, 2021, 385, e83.	13.9	675
2	Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. New England Journal of Medicine, 2022, 387, 21-34.	13.9	368
3	Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. New England Journal of Medicine, 2022, 386, 1288-1290.	13.9	356
4	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nature Medicine, 2021, 27, 2136-2143.	15.2	346
5	mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nature Medicine, 2021, 27, 1614-1621.	15.2	337
6	Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. New England Journal of Medicine, 2022, 386, 1804-1816.	13.9	311
7	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nature Communications, 2022, 13, .	5.8	188
8	Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting. Clinical Infectious Diseases, 2021, 73, e1830-e1840.	2.9	154
9	SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine, 2021, 35, 100861.	3.2	153
10	Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. JAMA - Journal of the American Medical Association, 2021, 326, 1930.	3.8	140
11	Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. Scientific Reports, 2021, 11, 6233.	1.6	117
12	Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses. Vaccines, 2020, 8, 668.	2.1	85
13	Characterizing the transitioning epidemiology of herpes simplex virus type 1 in the USA: model-based predictions. BMC Medicine, 2019, 17, 57.	2.3	75
14	Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. Emerging Infectious Diseases, 2021, 27, 1343-1352.	2.0	74
15	Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. Journal of Global Health, 2021, 11, 05005.	1.2	71
16	Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. Journal of Travel Medicine, 2021, 28, .	1.4	69
17	Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention. Journal of Viral Hepatitis, 2017, 24, 486-495.	1.0	61
18	Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. PLoS Medicine, 2021, 18, e1003879.	3.9	54

#	Article	IF	Citations
19	Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. Nature Communications, 2022, 13, 532.	5.8	53
20	SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar. Scientific Reports, 2021, 11, 18182.	1.6	49
21	Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant. Clinical Infectious Diseases, 2022, 75, e1188-e1191.	2.9	38
22	Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections. Journal of Travel Medicine, 2022, 29, .	1.4	37
23	Age could be driving variable SARS-CoV-2 epidemic trajectories worldwide. PLoS ONE, 2020, 15, e0237959.	1.1	35
24	Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020. Global Epidemiology, 2021, 3, 100068.	0.6	30
25	Characterizing the temporal evolution of the hepatitis C virus epidemic in Pakistan. Journal of Viral Hepatitis, 2018, 25, 670-679.	1.0	28
26	Characterizing key attributes of COVID-19 transmission dynamics in China's original outbreak: Model-based estimations. Global Epidemiology, 2020, 2, 100042.	0.6	27
27	Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. BMJ Innovations, 2021, 7, 327-336.	1.0	27
28	Vulnerability of Syrian refugees in Lebanon to COVID-19: quantitative insights. Conflict and Health, 2021, 15, 13.	1.0	25
29	Hepatitis C virus infection spontaneous clearance: Has it been underestimated?. International Journal of Infectious Diseases, 2018, 75, 60-66.	1.5	24
30	Epidemiological Differences in the Impact of COVID-19 Vaccination in the United States and China. Vaccines, 2021, 9, 223.	2.1	20
31	Treatment as prevention for hepatitis C virus in Pakistan: mathematical modelling projections. BMJ Open, 2019, 9, e026600.	0.8	17
32	Epidemiological Impact of Novel Preventive and Therapeutic HSV-2 Vaccination in the United States: Mathematical Modeling Analyses. Vaccines, 2020, 8, 366.	2.1	17
33	Characterizing the historical role of parenteral antischistosomal therapy in hepatitis C virus transmission in Egypt. International Journal of Epidemiology, 2020, 49, 798-809.	0.9	13
34	Forecasting the impact of diabetes mellitus on tuberculosis disease incidence and mortality in India. Journal of Global Health, 2019, 9, 020415.	1.2	12
35	Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO. The Lancet Gastroenterology and Hepatology, 2022, 7, 353-366.	3.7	10
36	Analytic Characterization of the Herpes Simplex Virus Type 2 Epidemic in the United States, 1950â€"2050. Open Forum Infectious Diseases, 2021, 8, ofab218.	0.4	8

#	Article	IF	Citations
37	Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatarâ€™s experience. Journal of Global Health, 2022, 12, 05004.	1.2	7
38	Use of routine HIV testing data for early detection of emerging HIV epidemics in high-risk subpopulations: A concept demonstration study. Infectious Disease Modelling, 2018, 3, 373-384.	1.2	4
39	Hepatitis C Virus in the Middle East and North Africa. , 2019, , 1-27.		4
40	Parameter identification for model of T cell proliferation in Lymphopenia conditions. Mathematical Biosciences, 2014, 251, 63-71.	0.9	3
41	Can the COVID-19 pandemic still be suppressed? Putting essential pieces together. Journal of Global Health Reports, 0, , .	1.0	3
42	SARS-CoV-2 infection rates in air passengers arriving in Qatar. Journal of Travel Medicine, 2021, 28, .	1.4	2
43	Human herpes simplex virus-6 (HHV-6) detection and seroprevalence among Qatari nationals and immigrants residing in Qatar. IJID Regions, 2022, 2, 90-95.	0.5	2
44	Modeling the population-level impact of treatment on COVID-19 disease and SARS-CoV-2 transmission. Epidemics, 2022, 39, 100567.	1.5	2
45	Analyzing inherent biases in SARS-CoV-2 PCR and serological epidemiologic metrics. BMC Infectious Diseases, 2022, 22, 458.	1.3	1
46	An Age-Structured Model for T Cell Homeostasis in Vivo. SIAM Journal on Applied Mathematics, 2014, 74, 1463-1485.	0.8	0
47	Hepatitis C Virus in the Middle East and North Africa. , 2021, , 3027-3052.		0
48	Parameters identification for a model of T cell homeostasis. Mathematical Biosciences and Engineering, 2015, 12, 917-936.	1.0	0